|
Oct 11
|
Roche wins first-line approval for PI3K inhibitor combo in breast cancer
|
|
Oct 11
|
Roche’s VENTANA CLDN18 assay gains CE mark
|
|
Oct 11
|
FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff
|
|
Oct 11
|
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
|
|
Oct 10
|
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
|
|
Oct 10
|
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
|
|
Oct 10
|
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
|
|
Oct 10
|
Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
|
|
Oct 9
|
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ...
|
|
Oct 9
|
Lineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ...
|
|
Oct 9
|
Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ...
|
|
Oct 8
|
Survey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general public
|
|
Oct 7
|
ONCY Stock Up on Regulatory Update From Breast Cancer Program
|
|
Oct 7
|
Scholar Rock scores with ‘surprise’ success in SMA drug study
|
|
Aug 30
|
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
|
|
Aug 30
|
The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
|
|
Aug 28
|
Five alternatives to Mag 7 stocks if you missed out on Nvidia
|
|
Aug 27
|
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
|
|
Aug 27
|
EC approves Roche’s monoclonal antibody PiaSky to treat PNH
|
|
Aug 27
|
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
|